Status:
UNKNOWN
Examination of Efficacy and Safety of Baricitinib in RA Patients
Lead Sponsor:
Shinshu University
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. Baricitinib treatment for 12 months 2. Biologics treatment for 12 mo...
Eligibility Criteria
Inclusion
- RA patients
Exclusion
- Not RA patients
- RA patients who are allergic to the drugs, refused to do this research, or who are pregnant
Key Trial Info
Start Date :
November 21 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 20 2025
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03755466
Start Date
November 21 2018
End Date
November 20 2025
Last Update
September 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yukio Nakamura
Matsumoto, Nagano, Japan, 3908621